Spruce Biosciences (SPRB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting called to order at 10:00 AM PT, with introductions of board members and executive officers.
Notice of meeting, proxy materials, and quorum confirmed; meeting conducted virtually with live webcast and Q&A session scheduled.
Board and executive committee updates
Three Class III directors nominated for election to serve until the 2029 annual meeting.
Board recommends votes for all nominees and proposals.
Shareholder proposals
Four proposals presented: election of directors, ratification of auditor, advisory vote on executive compensation, and preferred frequency of future say-on-pay votes.
Board recommends annual frequency for future advisory votes on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Spruce Biosciences
- TA-ERT advances toward BLA submission as finances and leadership strengthen.SPRB
Q1 202613 May 2026 - Annual meeting to elect directors, ratify auditor, and vote on executive pay and its frequency.SPRB
Proxy filing9 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and governance after a 1:75 reverse split.SPRB
Proxy filing9 Apr 2026 - Lead therapy for MPS IIIB advances toward Q4 BLA submission with strong clinical and regulatory momentum.SPRB
The Citizens Life Sciences Conference 202610 Mar 2026 - FDA supports accelerated approval; commercial and financial plans are on track for launch.SPRB
Leerink Global Healthcare Conference 20269 Mar 2026 - TA-ERT program progresses toward BLA submission as net loss narrows and cash runway extends.SPRB
Q4 20259 Mar 2026 - TA-ERT is BLA-ready for MPS IIIB, with durable efficacy, safety, and strong market potential.SPRB
Corporate presentation9 Mar 2026 - TA-ERT targets MPS IIIB with durable efficacy, aiming for FDA approval and $1B+ peak sales.SPRB
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Key CAH and PCOS data readouts expected in Q3, with a depression study launching in Q4.SPRB
Jefferies Global Healthcare Conference13 Feb 2026